CPT 0506U: EndoSign® Barrett’s Esophagus DNA Methylation Test

Headline: New CPT code 0506U identifies a proprietary methylation assay for Barrett’s esophagus

Lead: CPT code 0506U designates the EndoSign® Barrett’s Esophagus Test (Cyted Health Inc.), a proprietary next‑generation sequencing assay that evaluates DNA methylation patterns from esophageal cells and reports a likelihood score for Barrett’s esophagus. The code provides a standardized national identifier for billing and policy review of this single‑manufacturer laboratory test.

What this code represents and why it matters: CPT code 0506U is a PLA code reserved for one unique diagnostic assay. As molecular diagnostics proliferate, PLA codes like 0506U clarify when a result is tied to a specific commercial test, enabling payers and providers to track utilization, coverage, and clinical adoption for that exact product.

Key payers covered: Analysis includes major national payers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

What readers will learn: The publication outlines clinical context for Barrett’s esophagus screening and surveillance, explains the technical basis of the EndoSign® methylation assay, and presents benchmarks and policy considerations relevant to PLA‑coded tests. Readers will find information on billing identification, typical sites of service, and the role of a PLA code in payer coverage discussions.

Scope: National—covers code definition, clinical context, payer landscape, and policy implications. Data not available in the input is noted where applicable.

Billing Code Overview

CPT code 0506U is a Proprietary Laboratory Analyses (PLA) code that applies only to the EndoSign® Barrett’s Esophagus Test from Cyted Health Inc. The test uses next‑generation sequencing to analyze DNA methylation patterns in esophageal cells and generates a likelihood score for Barrett’s esophagus.

Service type: Proprietary laboratory diagnostic assay

Typical site of service: Clinical laboratory or reference laboratory processing esophageal cell specimens

Data not available in the input.

Clinical Context

A 55‑year‑old patient with chronic gastroesophageal reflux symptoms and endoscopic suspicion of Barrett’s esophagus provides an esophageal cell sample via brush or biopsied tissue collected during upper endoscopy. The sample is sent to a clinical laboratory that performs the EndoSign® Barrett’s Esophagus Test (Cyted Health Inc.), a next‑generation sequencing–based DNA methylation assay that produces a likelihood score for Barrett’s esophagus. The clinical workflow includes order entry by the gastroenterologist, collection of the specimen during EGD (esophagogastroduodenoscopy), specimen labeling and shipment to the performing laboratory, processing and sequencing in a certified molecular pathology lab, generation of the EndoSign® report, and transmission of results to the ordering provider for use in surveillance and management decisions. Typical site of service is an outpatient endoscopy suite, ambulatory surgical center, or hospital outpatient department, with laboratory processing performed at the proprietary testing laboratory.

Coding Specifications

Modifier	Description	When to Use
`00`	Default/No modifier	Use when no specific circumstances apply to the billed service
`26`	Professional component

Taxonomy Code	Specialty	Notes
2086S0105X	Gastroenterology	Gastroenterologists typically order and collect specimens during EGD for Barrett’s surveillance
207L00000X	Pathology	Pathologists or molecular pathologists oversee laboratory testing and result interpretation
208D00000X	General Surgery	Surgeons who perform esophageal procedures may order or coordinate testing
363LP0805X	Clinical Laboratory	Clinical laboratory directors and molecular diagnostic laboratories perform the assay

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`K22.7`	Barrett esophagus	Primary indication for EndoSign® testing to assess likelihood of Barrett’s esophagus
`K21.9`	Gastroesophageal reflux disease without esophagitis	Common clinical context prompting surveillance for Barrett’s esophagus
`R12`	Heartburn	Symptom that often leads to further evaluation and consideration of Barrett’s testing
`K22.8`	Other specified diseases of esophagus	Includes other esophageal conditions where molecular testing may be considered
`R19.7`	Change in bowel habit — Data not typical for this test	Not routinely associated but included only if clinically documented (placeholder)

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`43235`	Upper gastrointestinal endoscopy including biopsy, single or multiple	Often performed immediately before specimen collection for EndoSign®; provides tissue or brush samples
`88305`	Surgical pathology, gross and microscopic examination	May be used when formal biopsy specimens are submitted to pathology in addition to molecular testing
`81479`	Unlisted molecular pathology procedure	Occasionally used for reporting proprietary or novel molecular tests when a PLA code is not available; for EndoSign® use `0506U` instead
`0506U`	EndoSign® Barrett’s Esophagus Test (proprietary PLA)	Specific PLA code to report the EndoSign® methylation sequencing assay performed by Cyted Health Inc.
`99000`	Handling and/or conveyance of specimen for transfer from the physician to a laboratory	Used when specimen handling for off‑site testing incurs additional billable services

OpenPayer

Summary & Overview